Last Updated: March 25, 2026
The latest updates to the Medicare CBD program in 2026. Updated as new information becomes available. Bookmark this page and check back regularly.
Related: Program News Page | Complete Guide
March 25, 2026 — Program Status
The Substance Access BEI program officially launches April 1, 2026 for ACO REACH and Enhancing Oncology Model participants. CMS has published full implementation guidelines including product requirements, dosing documentation expectations, and safeguard requirements. The LEAD Model component begins January 1, 2027. See full details at innovation.cms.gov.
Key confirmed details as of this date:
- $500 per patient per year benefit confirmed
- Oral products only — gummies, tinctures, capsules, oral solutions
- Less than 0.3% delta-9 THC and less than 3mg total THC per serving required
- Third-party lab testing required for all products
- Farm Bill compliant source required
- State law compliance required
- CMS implementation plan approval required before any patient distribution
- No retail reimbursement pathway — physician-direct only
We update this post as new CMS announcements, rule changes, and program developments occur. Check back regularly or visit our dedicated news page for the most current information.
